利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

114 条记录 (耗时 0.03 秒)

    TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID
    6.
    发明申请
    TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID 有权
    用于减少尿酸的四唑化合物

    公开(公告)号：US20130336949A1

    公开(公告)日：2013-12-19

    申请号：US13783680

    申请日：2013-03-04

    申请人： Rita M. O'Neil ,  Wellstat Therapeutics Corporation

    发明人： James Dennen O'Neil ,  Shalini Sharma ,  Ramachandran Arudchandran

    IPC分类号： C07D257/04 ,  A61K45/06 ,  A61K31/41

    CPC分类号： C07D257/04 ,  A61K31/41 ,  A61K45/06

    摘要： Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.

    摘要翻译： 哺乳动物受试者中的尿酸通过给予式I化合物而降低尿酸的排泄。本发明化合物的尿酸降低作用用于治疗或预防多种病症，包括痛风，高尿酸血症，升高的 不符合常规诊断高尿酸血症，肾功能障碍，肾结石，心血管疾病，发展心血管疾病风险，肿瘤溶解综合征，认知障碍，早发性原发性高血压和恶性疟原虫的水平的尿酸水平， 诱发炎症。

    COMBINATION TREATMENT FOR METABOLIC DISORDERS
    9.
    发明申请
    COMBINATION TREATMENT FOR METABOLIC DISORDERS 审中-公开
    代谢障碍的组合治疗

    公开(公告)号：US20130137629A1

    公开(公告)日：2013-05-30

    申请号：US13749135

    申请日：2013-01-24

    申请人： WELLSTAT THERAPEUTICS CORPORATION

    发明人： Stephen D. Wolpe ,  Ramachandran Arudchandran ,  Reid W. von Borstel

    IPC分类号： A61K38/22 ,  A61K31/192

    CPC分类号： A61K38/22 ,  A61K31/192 ,  A61K31/5377

    摘要： Various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis can be treated with a compound selected from an incretin mimetic and a dipeptidyl peptidase IV inhibitor in combination with a Compound of Formula I or a pharmaceutically acceptable salt thereof Three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and m is 0, 2 or 4. R6 is hydrogen, O or hydroxy, and X is —OR7, wherein R7 is hydrogen or alkyl having from 1 to 3 carbon atoms; or R6 is hydrogen, and X is —NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl. When X is —NR8R9, hydroxy none of R1, R2, R3, R4 and R5 is hydroxy.

    摘要翻译： 可以用选自肠降血
    球蛋白模拟物和二肽基肽酶IV抑制剂的化合物与下列药物组合治疗各种代谢紊乱，例如胰岛素抵抗综合征，糖尿病，多囊卵巢综合征，高脂血症，脂肪肝疾病，恶病质，肥胖症，动脉粥样硬化和动脉硬化 式I化合物或其药学上可接受的盐R 1，R 2，R 3，R 4和R 5中的三个是氢，其余的独立地选自氢，卤素，羟基，甲基，乙基，全氟甲基，甲氧基，乙氧基， 和全氟甲氧基; R 6是氢，O或羟基，X是-OR 7，其中R 7是氢或具有1至3个碳原子的烷基; 或R6是氢，X是-NR8R9，其中R8是氢或羟基，R9是氢，甲基或乙基。 当X是-NR 8 R 9时，R 1，R 2，R 3，R 4和R 5不是羟基。